Rate Video

ESMO WCGIC 2020 | Nivolumab for CCA

ESMO WCGIC 2020

Bile Duct Cancer Gastrointestinal Cancer Antibodies FOLFOX Nivolumab

Richard Kim, MD, of the Moffitt Cancer Center, Tampa, FL, describes Phase II results of nivolumab in patients with advanced, refractory cholangiocarcinoma (CCA). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Regorafenib in refractory biliary tract cancer

SWOG S1310: trametinib vs 5-FU/capecitabine in refractory advanced biliary cancer

Richard Kim • 2 Jul 2020

Regorafenib + nivolumab in MMR proficient advanced CRC

Related Videos

Health-related quality of life in young CRC survivors

Afsaneh Barzi • 18 Jan 2021

Disparities in access to screening and variation of targets in different groups

Afsaneh Barzi • 18 Jan 2021

Onvansertib for second-line treatment of KRAS-mutated mCRC

Heinz-Josef Lenz • 17 Jan 2021

TAGS: trifluridine/tipiracil in metastatic gastric adenocarcinoma

Michele Ghidini • 17 Jan 2021